Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 4/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23806954 | 0.91 | CYP2D6 (0.34) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL25887824 | 0.89 | S1PR1 (0.33) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL23945342 | 0.86 | CA1 (0.32) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL25923473 | 0.86 | CYP2D6 (0.32) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL25123600 | 0.85 | LMNA (0.35) | CYP2D6TSHRUSP2 | |
| SCHEMBL23807071 | 0.84 | S1PR1 (0.32) | CYP2D6 | |
| SCHEMBL25702522 | 0.84 | CYP2D6 (0.34) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL25707175 | 0.84 | CYP2D6 (0.34) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL25110081 | 0.84 | S1PR1 (0.34) | CYP2D6TSHRUSP2HPGD | |
| SCHEMBL24673701 | 0.83 | S1PR1 (0.32) | CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.